No Data
No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Huashen Technology: 2024 Annual Performance Forecast
Chengdu Huasun Technology Group's Capsules Intended for Selection for National TCM Procurement; Shares Down 4%
Express News | Chengdu huasun technology group Inc., LTD.: Qilin Tongshu Capsules are intended to be selected for the national Chinese Patent Medicine procurement alliance centralized bulk procurement.
Express News | Chengdu huasun technology group inc., ltd.: A wholly-owned subsidiary provides a guarantee of 20 million yuan for the company.
Huashen Technology: Report for the third quarter of 2024